Although CBD products are growing in popularity, the Food and Drug Administration (FDA) consistently takes the position that the sale and marketing of CBD foods and dietary supplements is unlawful and that the use of CBD is dangerous. Though CBD is a no-no for the FDA, states have already adopted their own legal approaches to regulating these products, which are not necessarily consistent with the FDA’s current position and/or that altogether violate that position. This patchwork of often conflicting state regulations, combined with the lack of any formal federal legal pathway for the sale and marketing of CBD products, makes it nearly impossible for CBD stakeholders to meet compliance standards.
In light of this challenging regulatory landscape, this webinar will:
• Discuss strategies CBD companies should adopt to mitigate the risk of federal enforcement actions.
• Unscramble the patchwork of state regulations that CBD manufacturers, distributors and retailers must follow, particularly when engaged in e-commerce.
• Address labeling and marketing trends, including best practices to comply with rapidly changing laws and regulations.